Drugs / NM26-2198
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05859724 | May 2023 → Oct 2024 | atopic eczema | Yellow Jersey Therapeutics AG | Terminated | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | NM26-2198 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05859724 ↗ |
| Route | Subcutaneous | “for subcutaneous administration” NCT05859724 ↗ |